Related Experiment Video
Updated: Aug 2, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Penbutolol in hypertension: a pilot study with single daily doses
Abstract:
A pilot single-blind placebo controlled crossover within-patient study was undertaken in essential hypertension. In ten patients single daily doses of 25 mg and 50 mg and in two patients 25 mg, 50 mg and 100 mg were used. Satisfactory reductions in both systolic and diastolic blood pressure in the supine and erect postures were observed. Reduction in heart rate was of the order of 6-32%, there being no correlation between reductions in blood pressure and decrements in heart rate. Three patients were dropped from the final analyses. Seventy-eight per cent (7/9) of patients had a final diastolic pressure (lying) of 90 mm Hg or less. Single doses of penbutolol controlled blood pressure for at least twenty-four hours. At the end of two weeks on placebo medication, following nine weeks of active drug medication, blood pressure had reverted to near pre-treatment levels. Penbutolol was well tolerated.
Related Concept Videos
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Measurement of Blood Pressure
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Inhaled Medications
Hypertension III: Clinical Manifestations and Diagnostic Studies

